



Varicella Live Vaccine Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-20	130	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Varicella Live Vaccine market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Varicella Live Vaccine is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Varicella Live Vaccine is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Varicella Live Vaccine is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Varicella Live Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Panacea Biotec, Mitsubishi Tanabe Pharma Corporation and MedImmune, LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Varicella Live Vaccine market in terms of revenue (US\$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Varicella Live Vaccine Market by Company

Johnson & Johnson

Merck & Co., Inc.

Pfizer, Inc.
GlaxoSmithKline plc
Serum Institute of India Pvt. Ltd.
Sanofi Pasteur
Panacea Biotec
Mitsubishi Tanabe Pharma Corporation
MedImmune, LLC
Emergent BioSolutions, Inc.
Daiichi Sankyo
CSL Limited
Biological E
Bavarian Nordic
Astellas Pharma Inc.

Varicella Live Vaccine Segment by Type

Monovalent Vaccines
Multivalent Vaccines

Varicella Live Vaccine Segment by Application

Herpes Zoster Immunization
Measles Immunization
Chicken Pox Immunization
Others

Varicella Live Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Live Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Varicella Live Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Varicella Live Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Varicella Live Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Varicella Live Vaccine Market Size (2021-2032)
 - 2.2.2 Global Varicella Live Vaccine Sales (2021-2032)
 - 2.2.3 Global Varicella Live Vaccine Market Average Price (2021-2032)
- 2.3 Varicella Live Vaccine by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Monovalent Vaccines
 - 2.3.3 Multivalent Vaccines
- 2.4 Varicella Live Vaccine by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Herpes Zoster Immunization
 - 2.4.3 Measles Immunization
 - 2.4.4 Chicken Pox Immunization
 - 2.4.5 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Varicella Live Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Varicella Live Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Varicella Live Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Varicella Live Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Varicella Live Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Varicella Live Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Varicella Live Vaccine, Established Date
- 3.9 Global Varicella Live Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Johnson & Johnson
 - 4.1.1 Johnson & Johnson Company Information
 - 4.1.2 Johnson & Johnson Business Overview
 - 4.1.3 Johnson & Johnson Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Johnson & Johnson Varicella Live Vaccine Product Portfolio
 - 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Merck & Co., Inc.

- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Varicella Live Vaccine Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Pfizer, Inc.
 - 4.3.1 Pfizer, Inc. Company Information
 - 4.3.2 Pfizer, Inc. Business Overview
 - 4.3.3 Pfizer, Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Pfizer, Inc. Varicella Live Vaccine Product Portfolio
 - 4.3.5 Pfizer, Inc. Recent Developments
- 4.4 GlaxoSmithKline plc
 - 4.4.1 GlaxoSmithKline plc Company Information
 - 4.4.2 GlaxoSmithKline plc Business Overview
 - 4.4.3 GlaxoSmithKline plc Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio
 - 4.4.5 GlaxoSmithKline plc Recent Developments
- 4.5 Serum Institute of India Pvt. Ltd.
 - 4.5.1 Serum Institute of India Pvt. Ltd. Company Information
 - 4.5.2 Serum Institute of India Pvt. Ltd. Business Overview
 - 4.5.3 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio
 - 4.5.5 Serum Institute of India Pvt. Ltd. Recent Developments
- 4.6 Sanofi Pasteur
 - 4.6.1 Sanofi Pasteur Company Information
 - 4.6.2 Sanofi Pasteur Business Overview
 - 4.6.3 Sanofi Pasteur Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Sanofi Pasteur Varicella Live Vaccine Product Portfolio
 - 4.6.5 Sanofi Pasteur Recent Developments
- 4.7 Panacea Biotec
 - 4.7.1 Panacea Biotec Company Information
 - 4.7.2 Panacea Biotec Business Overview
 - 4.7.3 Panacea Biotec Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Panacea Biotec Varicella Live Vaccine Product Portfolio
 - 4.7.5 Panacea Biotec Recent Developments
- 4.8 Mitsubishi Tanabe Pharma Corporation
 - 4.8.1 Mitsubishi Tanabe Pharma Corporation Company Information
 - 4.8.2 Mitsubishi Tanabe Pharma Corporation Business Overview
 - 4.8.3 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio
 - 4.8.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
- 4.9 MedImmune, LLC
 - 4.9.1 MedImmune, LLC Company Information
 - 4.9.2 MedImmune, LLC Business Overview
 - 4.9.3 MedImmune, LLC Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.9.4 MedImmune, LLC Varicella Live Vaccine Product Portfolio
 - 4.9.5 MedImmune, LLC Recent Developments
- 4.10 Emergent BioSolutions, Inc.

- 4.10.1 Emergent BioSolutions, Inc. Company Information
- 4.10.2 Emergent BioSolutions, Inc. Business Overview
- 4.10.3 Emergent BioSolutions, Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio
- 4.10.5 Emergent BioSolutions, Inc. Recent Developments
- 4.11 Daiichi Sankyo
 - 4.11.1 Daiichi Sankyo Company Information
 - 4.11.2 Daiichi Sankyo Business Overview
 - 4.11.3 Daiichi Sankyo Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.11.4 Daiichi Sankyo Varicella Live Vaccine Product Portfolio
 - 4.11.5 Daiichi Sankyo Recent Developments
- 4.12 CSL Limited
 - 4.12.1 CSL Limited Company Information
 - 4.12.2 CSL Limited Business Overview
 - 4.12.3 CSL Limited Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.12.4 CSL Limited Varicella Live Vaccine Product Portfolio
 - 4.12.5 CSL Limited Recent Developments
- 4.13 Biological E
 - 4.13.1 Biological E Company Information
 - 4.13.2 Biological E Business Overview
 - 4.13.3 Biological E Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.13.4 Biological E Varicella Live Vaccine Product Portfolio
 - 4.13.5 Biological E Recent Developments
- 4.14 Bavarian Nordic
 - 4.14.1 Bavarian Nordic Company Information
 - 4.14.2 Bavarian Nordic Business Overview
 - 4.14.3 Bavarian Nordic Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.14.4 Bavarian Nordic Varicella Live Vaccine Product Portfolio
 - 4.14.5 Bavarian Nordic Recent Developments
- 4.15 Astellas Pharma Inc.
 - 4.15.1 Astellas Pharma Inc. Company Information
 - 4.15.2 Astellas Pharma Inc. Business Overview
 - 4.15.3 Astellas Pharma Inc. Varicella Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
 - 4.15.4 Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio
 - 4.15.5 Astellas Pharma Inc. Recent Developments

5 Global Varicella Live Vaccine Market Scenario by Region

- 5.1 Global Varicella Live Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Varicella Live Vaccine Sales by Region: 2021-2032
 - 5.2.1 Global Varicella Live Vaccine Sales by Region: 2021-2026
 - 5.2.2 Global Varicella Live Vaccine Sales by Region: 2027-2032
- 5.3 Global Varicella Live Vaccine Revenue by Region: 2021-2032
 - 5.3.1 Global Varicella Live Vaccine Revenue by Region: 2021-2026
 - 5.3.2 Global Varicella Live Vaccine Revenue by Region: 2027-2032
- 5.4 North America Varicella Live Vaccine Market Facts & Figures by Country
 - 5.4.1 North America Varicella Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Varicella Live Vaccine Sales by Country (2021-2032)
 - 5.4.3 North America Varicella Live Vaccine Revenue by Country (2021-2032)
 - 5.4.4 United States

5.4.5 Canada

5.4.6 Mexico

5.5 Europe Varicella Live Vaccine Market Facts & Figures by Country

5.5.1 Europe Varicella Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe Varicella Live Vaccine Sales by Country (2021-2032)

5.5.3 Europe Varicella Live Vaccine Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.5.9 Spain

5.5.10 Netherlands

5.5.11 Switzerland

5.5.12 Sweden

5.5.13 Poland

5.6 Asia Pacific Varicella Live Vaccine Market Facts & Figures by Country

5.6.1 Asia Pacific Varicella Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Varicella Live Vaccine Sales by Country (2021-2032)

5.6.3 Asia Pacific Varicella Live Vaccine Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 Taiwan

5.6.10 Southeast Asia

5.7 South America Varicella Live Vaccine Market Facts & Figures by Country

5.7.1 South America Varicella Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Varicella Live Vaccine Sales by Country (2021-2032)

5.7.3 South America Varicella Live Vaccine Revenue by Country (2021-2032)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

5.7.7 Colombia

5.8 Middle East and Africa Varicella Live Vaccine Market Facts & Figures by Country

5.8.1 Middle East and Africa Varicella Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Varicella Live Vaccine Sales by Country (2021-2032)

5.8.3 Middle East and Africa Varicella Live Vaccine Revenue by Country (2021-2032)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Türkiye

5.8.8 GCC Countries

6 Segment by Type

6.1 Global Varicella Live Vaccine Sales by Type (2021-2032)

6.1.1 Global Varicella Live Vaccine Sales by Type (2021-2032) & (k units)

6.1.2 Global Varicella Live Vaccine Sales Market Share by Type (2021-2032)

6.2 Global Varicella Live Vaccine Revenue by Type (2021-2032)

6.2.1 Global Varicella Live Vaccine Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Varicella Live Vaccine Revenue Market Share by Type (2021-2032)

6.3 Global Varicella Live Vaccine Price by Type (2021-2032)

7 Segment by Application

7.1 Global Varicella Live Vaccine Sales by Application (2021-2032)

7.1.1 Global Varicella Live Vaccine Sales by Application (2021-2032) & (k units)

7.1.2 Global Varicella Live Vaccine Sales Market Share by Application (2021-2032)

7.2 Global Varicella Live Vaccine Revenue by Application (2021-2032)

7.2.1 Global Varicella Live Vaccine Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Varicella Live Vaccine Revenue Market Share by Application (2021-2032)

7.3 Global Varicella Live Vaccine Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Varicella Live Vaccine Value Chain Analysis

8.1.1 Varicella Live Vaccine Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Varicella Live Vaccine Production Mode & Process

8.2 Varicella Live Vaccine Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Varicella Live Vaccine Distributors

8.2.3 Varicella Live Vaccine Customers

9 Global Varicella Live Vaccine Analyzing Market Dynamics

9.1 Varicella Live Vaccine Industry Trends

9.2 Varicella Live Vaccine Industry Drivers

9.3 Varicella Live Vaccine Industry Opportunities and Challenges

9.4 Varicella Live Vaccine Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Varicella Live Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Varicella Live Vaccine Sales (k units) of Manufacturers (2021-2026)
- Table 7: Global Varicella Live Vaccine Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Varicella Live Vaccine Revenue of Manufacturers (2021-2026)
- Table 9: Global Varicella Live Vaccine Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Varicella Live Vaccine Average Price (US\$/unit) of Manufacturers (2021-2026)
- Table 11: Global Varicella Live Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Varicella Live Vaccine, Product Type & Application
- Table 14: Global Varicella Live Vaccine Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Varicella Live Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Johnson & Johnson Company Information
- Table 19: Johnson & Johnson Business Overview
- Table 20: Johnson & Johnson Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 21: Johnson & Johnson Varicella Live Vaccine Product Portfolio
- Table 22: Johnson & Johnson Recent Developments
- Table 23: Merck & Co., Inc. Company Information
- Table 24: Merck & Co., Inc. Business Overview
- Table 25: Merck & Co., Inc. Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 26: Merck & Co., Inc. Varicella Live Vaccine Product Portfolio
- Table 27: Merck & Co., Inc. Recent Developments
- Table 28: Pfizer, Inc. Company Information
- Table 29: Pfizer, Inc. Business Overview
- Table 30: Pfizer, Inc. Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 31: Pfizer, Inc. Varicella Live Vaccine Product Portfolio
- Table 32: Pfizer, Inc. Recent Developments
- Table 33: GlaxoSmithKline plc Company Information
- Table 34: GlaxoSmithKline plc Business Overview
- Table 35: GlaxoSmithKline plc Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 36: GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio
- Table 37: GlaxoSmithKline plc Recent Developments
- Table 38: Serum Institute of India Pvt. Ltd. Company Information
- Table 39: Serum Institute of India Pvt. Ltd. Business Overview
- Table 40: Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 41: Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio
- Table 42: Serum Institute of India Pvt. Ltd. Recent Developments
- Table 43: Sanofi Pasteur Company Information
- Table 44: Sanofi Pasteur Business Overview
- Table 45: Sanofi Pasteur Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 46: Sanofi Pasteur Varicella Live Vaccine Product Portfolio
- Table 47: Sanofi Pasteur Recent Developments
- Table 48: Panacea Biotec Company Information
- Table 49: Panacea Biotec Business Overview

- Table 50: Panacea Biotec Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 51: Panacea Biotec Varicella Live Vaccine Product Portfolio
- Table 52: Panacea Biotec Recent Developments
- Table 53: Mitsubishi Tanabe Pharma Corporation Company Information
- Table 54: Mitsubishi Tanabe Pharma Corporation Business Overview
- Table 55: Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 56: Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio
- Table 57: Mitsubishi Tanabe Pharma Corporation Recent Developments
- Table 58: MedImmune, LLC Company Information
- Table 59: MedImmune, LLC Business Overview
- Table 60: MedImmune, LLC Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 61: MedImmune, LLC Varicella Live Vaccine Product Portfolio
- Table 62: MedImmune, LLC Recent Developments
- Table 63: Emergent BioSolutions, Inc. Company Information
- Table 64: Emergent BioSolutions, Inc. Business Overview
- Table 65: Emergent BioSolutions, Inc. Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 66: Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio
- Table 67: Emergent BioSolutions, Inc. Recent Developments
- Table 68: Daiichi Sankyo Company Information
- Table 69: Daiichi Sankyo Business Overview
- Table 70: Daiichi Sankyo Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 71: Daiichi Sankyo Varicella Live Vaccine Product Portfolio
- Table 72: Daiichi Sankyo Recent Developments
- Table 73: CSL Limited Company Information
- Table 74: CSL Limited Business Overview
- Table 75: CSL Limited Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 76: CSL Limited Varicella Live Vaccine Product Portfolio
- Table 77: CSL Limited Recent Developments
- Table 78: Biological E Company Information
- Table 79: Biological E Business Overview
- Table 80: Biological E Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 81: Biological E Varicella Live Vaccine Product Portfolio
- Table 82: Biological E Recent Developments
- Table 83: Bavarian Nordic Company Information
- Table 84: Bavarian Nordic Business Overview
- Table 85: Bavarian Nordic Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 86: Bavarian Nordic Varicella Live Vaccine Product Portfolio
- Table 87: Bavarian Nordic Recent Developments
- Table 88: Astellas Pharma Inc. Company Information
- Table 89: Astellas Pharma Inc. Business Overview
- Table 90: Astellas Pharma Inc. Varicella Live Vaccine Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 91: Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio
- Table 92: Astellas Pharma Inc. Recent Developments
- Table 93: Global Varicella Live Vaccine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 94: Global Varicella Live Vaccine Sales by Region (2021-2026) & (k units)
- Table 95: Global Varicella Live Vaccine Sales Market Share by Region (2021-2026)
- Table 96: Global Varicella Live Vaccine Sales by Region (2027-2032) & (k units)
- Table 97: Global Varicella Live Vaccine Sales Market Share by Region (2027-2032)
- Table 98: Global Varicella Live Vaccine Revenue by Region (2021-2026) & (US\$ Million)
- Table 99: Global Varicella Live Vaccine Revenue Market Share by Region (2021-2026)
- Table 100: Global Varicella Live Vaccine Revenue by Region (2027-2032) & (US\$ Million)
- Table 101: Global Varicella Live Vaccine Revenue Market Share by Region (2027-2032)
- Table 102: North America Varicella Live Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 103: North America Varicella Live Vaccine Sales by Country (2021-2026) & (k units)
- Table 104: North America Varicella Live Vaccine Sales by Country (2027-2032) & (k units)
- Table 105: North America Varicella Live Vaccine Revenue by Country (2021-2026) & (US\$ Million)

- Table 106: North America Varicella Live Vaccine Revenue by Country (2027-2032) & (US\$ Million)
- Table 107: Europe Varicella Live Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: Europe Varicella Live Vaccine Sales by Country (2021-2026) & (k units)
- Table 109: Europe Varicella Live Vaccine Sales by Country (2027-2032) & (k units)
- Table 110: Europe Varicella Live Vaccine Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: Europe Varicella Live Vaccine Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Asia Pacific Varicella Live Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: Asia Pacific Varicella Live Vaccine Sales by Country (2021-2026) & (k units)
- Table 114: Asia Pacific Varicella Live Vaccine Sales by Country (2027-2032) & (k units)
- Table 115: Asia Pacific Varicella Live Vaccine Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: Asia Pacific Varicella Live Vaccine Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: South America Varicella Live Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 118: South America Varicella Live Vaccine Sales by Country (2021-2026) & (k units)
- Table 119: South America Varicella Live Vaccine Sales by Country (2027-2032) & (k units)
- Table 120: South America Varicella Live Vaccine Revenue by Country (2021-2026) & (US\$ Million)
- Table 121: South America Varicella Live Vaccine Revenue by Country (2027-2032) & (US\$ Million)
- Table 122: Middle East and Africa Varicella Live Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 123: Middle East and Africa Varicella Live Vaccine Sales by Country (2021-2026) & (k units)
- Table 124: Middle East and Africa Varicella Live Vaccine Sales by Country (2027-2032) & (k units)
- Table 125: Middle East and Africa Varicella Live Vaccine Revenue by Country (2021-2026) & (US\$ Million)
- Table 126: Middle East and Africa Varicella Live Vaccine Revenue by Country (2027-2032) & (US\$ Million)
- Table 127: Global Varicella Live Vaccine Sales by Type (2021-2026) & (k units)
- Table 128: Global Varicella Live Vaccine Sales by Type (2027-2032) & (k units)
- Table 129: Global Varicella Live Vaccine Sales Market Share by Type (2021-2026)
- Table 130: Global Varicella Live Vaccine Sales Market Share by Type (2027-2032)
- Table 131: Global Varicella Live Vaccine Revenue by Type (2021-2026) & (US\$ Million)
- Table 132: Global Varicella Live Vaccine Revenue by Type (2027-2032) & (US\$ Million)
- Table 133: Global Varicella Live Vaccine Revenue Market Share by Type (2021-2026)
- Table 134: Global Varicella Live Vaccine Revenue Market Share by Type (2027-2032)
- Table 135: Global Varicella Live Vaccine Price by Type (2021-2026) & (US\$/unit)
- Table 136: Global Varicella Live Vaccine Price by Type (2027-2032) & (US\$/unit)
- Table 137: Global Varicella Live Vaccine Sales by Application (2021-2026) & (k units)
- Table 138: Global Varicella Live Vaccine Sales by Application (2027-2032) & (k units)
- Table 139: Global Varicella Live Vaccine Sales Market Share by Application (2021-2026)
- Table 140: Global Varicella Live Vaccine Sales Market Share by Application (2027-2032)
- Table 141: Global Varicella Live Vaccine Revenue by Application (2021-2026) & (US\$ Million)
- Table 142: Global Varicella Live Vaccine Revenue by Application (2027-2032) & (US\$ Million)
- Table 143: Global Varicella Live Vaccine Revenue Market Share by Application (2021-2026)
- Table 144: Global Varicella Live Vaccine Revenue Market Share by Application (2027-2032)
- Table 145: Global Varicella Live Vaccine Price by Application (2021-2026) & (US\$/unit)
- Table 146: Global Varicella Live Vaccine Price by Application (2027-2032) & (US\$/unit)
- Table 147: Key Raw Materials
- Table 148: Raw Materials Key Suppliers
- Table 149: Varicella Live Vaccine Distributors List
- Table 150: Varicella Live Vaccine Customers List
- Table 151: Varicella Live Vaccine Industry Trends
- Table 152: Varicella Live Vaccine Industry Drivers
- Table 153: Varicella Live Vaccine Industry Restraints
- Table 154: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Varicella Live Vaccine Product Image
- Figure 5: Global Varicella Live Vaccine Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Varicella Live Vaccine Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Varicella Live Vaccine Sales (2021-2032) & (k units)
- Figure 8: Global Varicella Live Vaccine Average Price (US\$/unit) & (2021-2032)
- Figure 9: Monovalent Vaccines Product Image
- Figure 10: Multivalent Vaccines Product Image
- Figure 11: Herpes Zoster Immunization Product Image
- Figure 12: Measles Immunization Product Image

- Figure 13: Chicken Pox Immunization Product Image
- Figure 14: Others Product Image
- Figure 15: Global Varicella Live Vaccine Revenue Share by Manufacturers in 2025
- Figure 16: Global Manufacturers of Varicella Live Vaccine, Manufacturing Sites & Headquarters
- Figure 17: Global Top 5 and 10 Varicella Live Vaccine Players Market Share by Revenue in 2025
- Figure 18: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 19: Global Varicella Live Vaccine Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 20: Global Varicella Live Vaccine Sales by Region in 2025
- Figure 21: Global Varicella Live Vaccine Revenue by Region in 2025
- Figure 22: North America Varicella Live Vaccine Market Size by Country in 2025
- Figure 23: North America Varicella Live Vaccine Sales Market Share by Country (2021-2032)
- Figure 24: North America Varicella Live Vaccine Revenue Market Share by Country (2021-2032)
- Figure 25: United States Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Canada Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Mexico Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Europe Varicella Live Vaccine Market Size by Country in 2025
- Figure 29: Europe Varicella Live Vaccine Sales Market Share by Country (2021-2032)
- Figure 30: Europe Varicella Live Vaccine Revenue Market Share by Country (2021-2032)
- Figure 31: Germany Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: France Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: U.K. Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Italy Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Russia Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Spain Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Netherlands Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Switzerland Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Sweden Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Poland Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Asia Pacific Varicella Live Vaccine Market Size by Country in 2025
- Figure 42: Asia Pacific Varicella Live Vaccine Sales Market Share by Country (2021-2032)
- Figure 43: Asia Pacific Varicella Live Vaccine Revenue Market Share by Country (2021-2032)
- Figure 44: China Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Japan Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: South Korea Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: India Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Australia Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Taiwan Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: South America Varicella Live Vaccine Market Size by Country in 2025
- Figure 53: South America Varicella Live Vaccine Sales Market Share by Country (2021-2032)
- Figure 54: South America Varicella Live Vaccine Revenue Market Share by Country (2021-2032)
- Figure 55: Brazil Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Argentina Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Chile Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Colombia Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Middle East and Africa Varicella Live Vaccine Market Size by Country in 2025
- Figure 60: Middle East and Africa Varicella Live Vaccine Sales Market Share by Country (2021-2032)
- Figure 61: Middle East and Africa Varicella Live Vaccine Revenue Market Share by Country (2021-2032)
- Figure 62: Egypt Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: South Africa Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: Israel Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Türkiye Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: GCC Countries Varicella Live Vaccine Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Global Varicella Live Vaccine Sales Market Share by Type (2021-2032)
- Figure 68: Global Varicella Live Vaccine Revenue Market Share by Type (2021-2032)
- Figure 69: Global Varicella Live Vaccine Price (US\$/unit) by Type (2021-2032)
- Figure 70: Global Varicella Live Vaccine Sales Market Share by Application (2021-2032)
- Figure 71: Global Varicella Live Vaccine Revenue Market Share by Application (2021-2032)
- Figure 72: Global Varicella Live Vaccine Price (US\$/unit) by Application (2021-2032)
- Figure 73: Varicella Live Vaccine Value Chain
- Figure 74: Varicella Live Vaccine Production Mode & Process
- Figure 75: Direct Comparison with Distribution Share
- Figure 76: Distributors Profiles
- Figure 77: Varicella Live Vaccine Industry Opportunities and Challenges

